Market Place
Sourcing Support
Marinus trims workforce by 45% after pair of clinical stumbles
13 Nov 2024 //
FIERCE PHARMA
Marinus Pharma Business Update & Reports Q3 2024 Financial Results
12 Nov 2024 //
BUSINESSWIRE
Marinus to end further Ztalmy development after another trial miss
24 Oct 2024 //
FIERCE PHARMA
Marinus Pharmaceuticals Announces Results From TrustTSC Trial
24 Oct 2024 //
BUSINESSWIRE
Marinus Presents Data From Phase 3 RAISE Trial At Neurocritical Care Meeting
17 Oct 2024 //
BUSINESSWIRE
Marinus Strengthens IP Estate With Patent For ZTALMY® Regimens
15 Oct 2024 //
BUSINESSWIRE
Marinus Pharma Announces Presentations At NCS 2024 Meeting
09 Oct 2024 //
BUSINESSWIRE
Marinus Pharma Announces Inducement Grants Under Nasdaq LR 5635(C)(4)
08 Oct 2024 //
BUSINESSWIRE
Marinus Pharmaceuticals to Highlight Clinical Progress
20 Sep 2024 //
BUSINESSWIRE
Marinus Pharmaceuticals Announces Investor & Analyst Day Agenda
12 Sep 2024 //
BUSINESSWIRE
Marinus To Present At Cantor Global Healthcare Conference
10 Sep 2024 //
BUSINESSWIRE
Marinus To Host Investor And Analyst Day On September 20, 2024
19 Aug 2024 //
BUSINESSWIRE
Marinus Pharma Reports Q2 2024 Results And Business Update
13 Aug 2024 //
BUSINESSWIRE
Marinus Pharmaceuticals To Report Q2 2024 Results On August 13
30 Jul 2024 //
BUSINESSWIRE
Ganaxolone Approved In China For CDKL5 Deficiency Disorder Seizures
18 Jul 2024 //
BUSINESSWIRE
Marinus reports mixed Phase 3 results on IV seizure drug
18 Jun 2024 //
FIERCE PHARMA
With investor lawsuit and trial flop, troubles mount for Marinus
17 Jun 2024 //
FIERCE PHARMA
Marinus Pharma Announces Topline Results From Phase 3 RAISE Trial Of Ganaxolone
17 Jun 2024 //
BUSINESSWIRE
Marinus Announces Updates For Tuberous Sclerosis Program
17 May 2024 //
BUSINESSWIRE
Marinus Pharmaceuticals: Business Update, Q1 2024 Financials
08 May 2024 //
BUSINESSWIRE
Marinus lays off 20% to steady ship after IV seizure med issues
08 May 2024 //
FIERCE BIOTECH
Marinus To Present At RBC Healthcare Conference 2024
02 May 2024 //
BUSINESSWIRE
Marinus Q1 2024 Results, Business Update On May 8
01 May 2024 //
BUSINESSWIRE
Marinus seizure med fails at interim analysis; shares plummet
16 Apr 2024 //
FIERCE PHARMA
Marinus RAISE Update, Prelim Q1 2024 Results
15 Apr 2024 //
BUSINESSWIRE
Marinus Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
05 Apr 2024 //
BUSINESSWIRE
Marinus Comments on Patent Challenge by Ovid & Provides Update
27 Mar 2024 //
BUSINESSWIRE
Ovid asks USPTO to review Marinus` patent around serious seizure condition
27 Mar 2024 //
ENDPTS
Marinus Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
05 Mar 2024 //
BUSINESSWIRE
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
21 Feb 2024 //
BUSINESSWIRE
Marinus to Report Fourth Quarter and Full Year 2023 Financial Results
20 Feb 2024 //
BUSINESSWIRE
Marinus Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
16 Feb 2024 //
BUSINESSWIRE
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023
04 Jan 2024 //
BUSINESSWIRE
Marinus Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04 Jan 2024 //
BUSINESSWIRE
Marinus Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
07 Dec 2023 //
BUSINESSWIRE
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023
20 Nov 2023 //
BUSINESSWIRE
Marinus to Present at the 6th Annual Evercore ISI HealthCONx Conference
14 Nov 2023 //
BUSINESSWIRE
Marinus Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
09 Nov 2023 //
BUSINESSWIRE
Marinus Initiates Global Access Program for ZTALMY Oral Suspension CV
07 Nov 2023 //
BUSINESSWIRE
Marinus Pharmaceuticals Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
BUSINESSWIRE
Marinus Pharmaceuticals to Report Third Quarter 2023 Financial Results
24 Oct 2023 //
BUSINESSWIRE
Marinus Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06 Oct 2023 //
BUSINESSWIRE
Marinus Pharmac to Present at the 2023 Cantor Global Healthcare Conference
21 Sep 2023 //
BUSINESSWIRE
Marinus Highlights Advancing Pipeline and Commercial Strategy
19 Sep 2023 //
BUSINESSWIRE
Marinus Announces Speakers for Hybrid Investor & Analyst Event on September 19
12 Sep 2023 //
BUSINESSWIRE
Marinus Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06 Sep 2023 //
BUSINESSWIRE
Marinus to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
17 Aug 2023 //
BUSINESSWIRE
Marinus Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
11 Aug 2023 //
BUSINESSWIRE
Marinus Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
BUSINESSWIRE
Marinus Announces EC Approval of ZTALMY for Epileptic Seizures
01 Aug 2023 //
BUSINESSWIRE
Marinus to Report Second Quarter 2023 Financial Results on August 10, 2023
27 Jul 2023 //
BUSINESSWIRE
Marinus Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
13 Jul 2023 //
BUSINESSWIRE
Marinus Announces New Method of Use Patent Granted for IV Ganaxolone
21 Jun 2023 //
BUSINESSWIRE
Marinus Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
02 Jun 2023 //
BUSINESSWIRE
Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY
26 May 2023 //
BUSINESSWIRE
Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting
17 May 2023 //
BUSINESSWIRE
Marinus Strengthens Board of Directors with Appointment of Sarah Noonberg
17 May 2023 //
BUSINESSWIRE
Marinus Provides Business Update & Reports First Quarter 2023 Financial Results
11 May 2023 //
BUSINESSWIRE
Marinus Pharmaceuticals Announces Inducement Grants UnderNasdaq Listing Rule
09 May 2023 //
BUSINESSWIRE
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
03 May 2023 //
BUSINESSWIRE
